Ipamorelin

What it is

Ipamorelin is a GHRP — a peptide that triggers growth hormone release by mimicking ghrelin at the ghrelin receptor. Compared to other GHRPs (GHRP-2, GHRP-6, hexarelin) it is selective: it stimulates GH release without much effect on cortisol, prolactin or hunger.

It is the default partner to CJC-1295 in community "GH stack" protocols.

History

Developed in the late 1990s by Novo Nordisk. Selectivity was the whole design goal — earlier GHRPs all caused hunger and prolactin spikes.

How it works

Binds to the ghrelin receptor in the pituitary and stimulates a clean GH pulse. Works synergistically with GHRH analogues like CJC-1295.

Dosage

• Typical: 100–300 mcg per injection, 1–3 times daily.
• Best paired 1:1 with CJC-1295 no-DAC for synergistic GH release.
• Time around natural pulses: before bed, fasted morning, or post-workout.

How it is taken

• Subcutaneous belly injection with an insulin pin.

How to reconstitute

• A 5 mg vial with 2 ml of BAC water gives 2.5 mg/ml. A 100 mcg dose is 4 units on a 1 ml insulin syringe.
• Frequently blended with CJC-1295 in the same vial for convenience.

How it should arrive

Sealed glass vial, white fluffy powder.

How it should look once reconstituted

Clear colourless solution.

What to expect, and when

• Sleep quality: noticeable in 1–2 weeks.
• Recovery: 4–8 weeks.
• Body composition: small and slow over months.

Side effects

• Minor head rush.
• Some tingling.
• Vivid dreams.
• Hunger is far less of an issue than with other GHRPs.

Risks

• Theoretical long-term GH/IGF-1 cancer-promotion concern (same as for the class).
• WADA prohibited.

Potential gains

• Cleaner GH stimulation than other GHRPs.
• Improved sleep, recovery, body composition over 8–12 weeks of consistent use.

Other useful information

If you only run one peptide pair for GH, this is the partner half. CJC-1295 + ipamorelin at 100/100 mcg, twice daily, is the most common community protocol.